Key result
Pravastatin use shows no association with 5-year cancer incidence in patients with CHD.
Why the study?
The potential long-term carcinogenicity of statins remains debated despite established short-term safety.
Does pravastatin use increase the five-year incidence of cancer in patients with coronary heart disease?
Population
263 coronary heart disease patients from Osaka prefecture admitted between 1991 and 1995
Comparison
Pravastatin use vs no pravastatin use
Design
Cohort study
Follow-up
5 years
Authors
Loading...
No increased 5-year cancer risk with pravastatin in CHD patients; leaves open long-term effects and warrants larger prospective studies before practice change.
Cohort (n=263)
No
Does pravastatin use increase the five-year incidence of cancer in patients with coronary heart disease?
Hazard Ratio: 0.78 (95% CI 0.18–3.46)
Pravastatin use over 5 years does not appear to increase overall cancer risk in patients with coronary heart disease, supporting its long-term safety.
Sato et al. (2006) conducted a cohort in Coronary heart disease (n=263). Pravastatin vs. Non-medicated was evaluated on All cancer incidence (HR 0.78, 95% CI 0.18-3.46). Pravastatin use for 5 years did not significantly alter the overall risk of cancer incidence in patients with coronary heart disease (HR 0.78).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: